The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Official Title: Local Substudy Associated to the International Study MO19390 to Determine the BRCA1 Gene mRNA Expression as a Predictive Marker of Response to Chemotherapy
Study ID: NCT00642824
Brief Summary: This single arm genetic substudy of MO19390 will test the hypothesis that there is a positive relationship between mRNA BRCAI levels and the response to different chemotherapy combinations plus Avastin. A subset of patients participating in MO19390, and receiving Avastin 15mg/kg iv on day 1 and subsequently once every 3 weeks, will undergo BRCAI mRNA expression determination. Depending on the BRCAI mRNA level (low, medium or high) they will receive a different chemotherapy regimen in combination with Avastin: a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel. Avastin treatment will continue after completion of chemotherapy cycles until disease progression, and the target sample size is 100-500 individuals.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Alcorcon, , Spain
, Alcoy, , Spain
, Alicante, , Spain
, Badalona, , Spain
, Barakaldo, , Spain
, Burgos, , Spain
, Elche, , Spain
, Girona, , Spain
, Huesca, , Spain
, La Laguna, , Spain
, Las Palmas de Gran Canaria, , Spain
, Lugo, , Spain
, Madrid, , Spain
, Madrid, , Spain
, Madrid, , Spain
, Murcia, , Spain
, Palma de Mallorca, , Spain
, Pamplona, , Spain
, Salamanca, , Spain
, Valencia, , Spain
, Valencia, , Spain
, Zaragoza, , Spain
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR